Loading data for NNVC — first visit, this takes a few seconds.

Preisalarm

NanoViricides Inc. (NNVC)

NYSE American: NNVC · Echtzeitkurs · USD

1.24

-0.04 (-3.13%)

Zum Schluss: Aug 28, 2026, 3:59 PM

Kurs, die wichtigsten Kennzahlen und die neuesten Nachrichten an einem Ort.

-3.13% (1D)

Geld	n/a
Marktkapitalisierung	31.65 Mio
Umsatz (TTM)	n/a
Nettogewinn (TTM)	-8.09 Mio
	1.69
	-0.44
	n/a
	-3.54
KBV (TTM)	2.93
KUV (TTM)	n/a
Termin Quartalszahlen	n/a

Brief	n/a
Volumen	187,960
Ø Vol. (20D)	351,955
Eröffnung	1.26
Vortagesschluss	1.28
Tagesspanne	1.22 - 1.28
52-Wk Range	0.85 - 2.23
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über NNVC

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections com...

[Mehr lesen]

Branche Biotechnology

Sektor Healthcare

IPO Datum Oct 26, 2005

Mitarbeiter 7

Börse NYSE American

Tickersymbol NNVC

Website https://www.nanoviricides.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von NanoViricides 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -9.47 Mio, ein Anstieg von 14.14 %.

Finanzberichte

Gewinnüberraschung

NanoViricides hat die Quartalszahlen am May 15, 2026 veröffentlicht:

Umsatz von $0 verfehlt die Erwartungen um $0, mit NaN% Wachstum im Jahresvergleich.
EPS von -0.09 verfehlt die Erwartungen um -0.01, mit 43.75% Wachstum im Jahresvergleich.

Nachrichten

vor 1 Monat · Stocktwits

NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola

The biotech firm said it is progressing towards a Phase II clinical trial of its antiviral drug NV-387 for the Bundibugyo Ebola outbreak in the Democratic Republic of Congo.

vor 2 Monaten · IPO-Edge.com

REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan

Watch Fireside Chat Below, or Click HERE: Exec Edge hosted a fireside chat with NanoViricides, Inc. (NYSE: NNVC) President and Executive Chairman Anil R. Diwan, PhD, moderated by IPO Edge […]

vor 3 Monaten · Proactive

NanoViricides closes $2M direct offering

NanoViricides (NYSE-A:NNVC) announced the closing of its previously disclosed registered direct offering, raising about $2 million in gross proceeds before fees and expenses. The clinical-stage antivi...

vor 3 Monaten · Proactive

NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak

NanoViricides (NYSE-A:NNVC), the US clinical-stage drugmaker, has said its lead drug candidate NV-387 could be effective against the Bundibugyo strain of Ebola virus that has prompted the World Health...

vor 3 Monaten · Proactive

NanoViricides to raise $2M in registered direct offering

NanoViricides (NYSE-A:NNVC) said it has entered into a securities purchase agreement with a single institutional investor for gross proceeds of approximately $2 million in a registered direct offering...

Seite 1 von 2

NanoViricides Inc. (NNVC)